What Researchers Did
A small clinical trial investigated the effects of 60 sessions of intermittent hyperbaric oxygen therapy (HBOT) on old human participants.
What They Found
The study found that intermittent HBOT resulted in increased mean telomere length of immune cells, including B cells, natural killer cells, T helper, and cytotoxic T lymphocytes. Moreover, there was a reduction in CD28, a marker associated with cellular aging.
What This Means for Canadian Patients
These findings suggest that hyperbaric oxygen therapy might offer a non-pharmacological approach to potentially slow cellular aging processes in older adults. If confirmed by larger studies, this could lead to new strategies for maintaining immune health and vitality.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The abstract indicates this was a small clinical trial, suggesting the need for larger studies to confirm these preliminary findings.